Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SUPN stock price vs NXPI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NXPI's multiple
Needs NXPI P/S.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SUPN FY 2025 (ended Dec 31, 2025) · NXPI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
NXP Semiconductors N.V. · implied price per share
Bear
$89.63
Base
$105.45
Bull
$121.26
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
1.11x
Net debt / EBITDA
Leverage against operating earnings
-6.69x
1.90x
Cash and equivalents
Liquid reserves on the balance sheet
$496.66M
$3.27B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
SUPN vs JAZZ
INCYTE CORP
SUPN vs INCY
ANI PHARMACEUTICALS INC
SUPN vs ANIP
Vanda Pharmaceuticals Inc.
SUPN vs VNDA
Harmony Biosciences Holdings, Inc.
SUPN vs HRMY
Qualcomm Incorporated
SUPN vs QCOM
Broadcom Inc.
SUPN vs AVGO
Texas Instruments Incorporated
SUPN vs TXN
NVIDIA Corporation
SUPN vs NVDA
Intel Corporation
SUPN vs INTC
$23.23M
$11.18B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SUPN can convert its 89.6% gross margin and 8.6% revenue growth into sustained operating profitability, then the stock looks like a relative value opportunity because the current price is below the P/S-implied value and near the top of its historical band; if not, the DCF and weak quality scores argue for caution.
On the provided P/S-based framework, SUPN's current price of $48.05 sits below the implied price of $70.23, suggesting 46.2% upside. However, the comparison is mixed because SUPN trades at 3.9x P/S versus NXPI at 5.6x, while other profitability-based multiples and the DCF range point to a much less supportive valuation.
Supporting Metrics
